Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

Helen M. Colhoun; D. J. Betteridge; Paul N. Durrington; G. A. Hitman; H. A. W. Neil; Shona Livingstone; Margaret J. Thomason; Michael I. Mackness; Valentine Charlton-Menys; John Fuller

doi:10.1016/s0140-6736(04)16895-5

Keywords

MedicineAtorvastatinType 2 diabetesInternal medicineDiabetes mellitusClinical endpointPlaceboAlbuminuriaStatinRosuvastatinCholesterolRandomized controlled trialDiseaseEndocrinology

Affiliated Institutions

Related Publications

Baseline Characteristics of Participants in the JUPITER Trial, A Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy Among Individuals With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein

Paul M. Ridker , Francisco Antônio Helfenstein Fonseca , Jacques Genest +10 more

2007 The American Journal of Cardiology 125 citations

Cholesterol reduction and its impact on coronary artery disease and total mortality

Ingar Holme

1995 The American Journal of Cardiology 60 citations

Rosuvastatin in the Primary Prevention of Cardiovascular Disease Among Patients With Low Levels of Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein

Paul M. Ridker

2003 Circulation 422 citations

Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?

John R. Guyton , David M. Herrington , Mary P. McGowan +3 more

The Treating to New Targets (TNT) trial is a parallel-group study that has randomized 10,003 patients from 14 countries to double-blind treatment with either atorvastatin 10 or ...

2004 The American Journal of Cardiology 198 citations

Statins: Beneficial or Adverse for Glucose Metabolism

Jun Sasaki , Mikio Iwashita , Suminori Kono

Large-scale clinical trials have established that statin use for lowering blood cholesterol is beneficial in reducing atherosclerotic cardiovascular diseases in different popula...

2006 Journal of Atherosclerosis and Thromb... 82 citations

Publication Info

Year: 2004
Type: article
Volume: 364
Issue: 9435
Pages: 685-696
Citations: 3751
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

3751

OpenAlex

Cite This

APA Style

                            
                                
                                    Helen M. Colhoun, 
                                
                                    D. J. Betteridge, 
                                
                                    Paul N. Durrington
                                
                                et al.
                            
                            (2004). 
                            Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. 
                            The Lancet
                            , 364
                            (9435)
                            , 685-696.
                            https://doi.org/10.1016/s0140-6736(04)16895-5
                        

Identifiers

DOI: 10.1016/s0140-6736(04)16895-5